BOYEN THERAPEUTICS, INC.

 

Area: Pharmaceutical and Medical Devices

Booth No: L225

Website: http://www.boyentherapeutics.com/

 

Exhibitor Profile

 

BoYen Therapeutics Inc. has a proprietary prodrug platform that enables chemosynthesis modifications to create patentable new drug candidates, for treatment of new indications.
Our pipeline comes with immense commercial values. Currently, two candidates are under development. BY-101 is an USFDA designated orphan drug with a 7-year marketing exclusivity; it is intended for the treatment of acute myeloid leukemia (AML). BYT-1007 is patented drug candidate for the treatment of multiple sclerosis.

 

Brands

 

BOYEN THERAPEUTICS

 

Exhibit Products

 

• 

  BYT-3156 prodrug

• 

  BY-103 prodrug

• 

  BY-102 prodrug

• 

  BY-101 (injectable)

 

 

 

back